Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Prevalence of RFC1-Mediated Spinocerebellar Ataxia in a United States Ataxia Cohort
Movement Disorders
P7 - Poster Session 7 (5:30 PM-6:30 PM)
3-005

We evaluated the prevalence of recently identified repeat-expansion disorders in an undiagnosed ataxia cohort from the United States.

Repeat expansions in RFC1 and DAB1 have recently been identified as causing cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) and spinocerebellar ataxia 37 (SCA37), respectively, but their prevalence in the United States is unknown.

A cohort of 596 patients with undiagnosed familial or sporadic cerebellar ataxia were evaluated at a tertiary referral ataxia center and excluded for common genetic causes of cerebellar ataxia. Patients were then screened for the presence of pathogenic repeat expansions in RFC1 (AAGGG) and DAB1 (ATTTC) using fluorescent repeat primed polymerase chain reaction (RP-PCR). Two additional undiagnosed ataxia cohorts from different centers, totaling 96 and 13 patients respectively, were subsequently screened for RFC1 resulting in a combined 705 subjects tested.

In the initial cohort, 42 samples were identified with one expanded allele in the RFC1 gene (7.0%), and 9 had two expanded alleles (1.5%). For the additional cohorts, we found 12 heterozygous samples (12.5%) and 7 biallelic samples (7.3%) in the larger cohort, and 1 heterozygous sample (7.7%) and 3 biallelic samples (23%) in the second. In total, 19 patients were identified with biallelic repeat expansions in RFC1 (2.7%). Of these 19 patients, 6 (32%) had a clinical diagnosis of CANVAS, 10 had cerebellar ataxia with neuropathy (53%), and 3 had spinocerebellar ataxia (16%). No patients were identified with expansions in the DAB1 gene.

In a large undiagnosed ataxia cohort from the United States, biallelic pathogenic repeat expansion in RFC1 was observed in 2.7%. Testing should be strongly considered in ataxia patients, especially those with CANVAS or neuropathy.
Authors/Disclosures
Brent L. Fogel, MD, PhD, FÂé¶¹´«Ã½Ó³»­ (UCLA Neurology)
PRESENTER
Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for National Ataxia Foundation. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Ataxia Global Initiative. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Today. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology Genetics. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Frontiers in Genetics. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Genes. Dr. Fogel has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neuromarkers. The institution of Dr. Fogel has received research support from the National Institutes of Health. The institution of Dr. Fogel has received research support from the National Ataxia Foundation. The institution of an immediate family member of Dr. Fogel has received research support from the National Institutes of Health, the National Science Foundation, and the Department of Defense. The institution of Dr. Fogel has received research support from US Department of Defense .
No disclosure on file
No disclosure on file
Claudio M. De Gusmao, MD Dr. DeGusmao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Mendelics Genomic Analysis. Dr. DeGusmao has received personal compensation in the range of $0-$499 for serving as a Consultant for EBSCO publishing. Dr. DeGusmao has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Clinical Outcome Solutions. Dr. DeGusmao has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for PTC Therapeuthics. The institution of Dr. DeGusmao has received research support from FDA.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Vikram Khurana, MD, PhD (Kings County Hospital) Dr. Khurana has received personal compensation for serving as an employee of DaCapo BrainScience. An immediate family member of Dr. Khurana has received personal compensation for serving as an employee of Arbor Therapeutics. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Sanofi. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Yoda Pharmaceuticals. Dr. Khurana has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Lundbeck. Dr. Khurana has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for DaCapo Brainscience. Dr. Khurana has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Mission MSA. Dr. Khurana has stock in DaCapo Brainscience. The institution of Dr. Khurana has received research support from Sanofi. The institution of Dr. Khurana has received research support from Janssen. The institution of Dr. Khurana has received research support from Biohaven. The institution of Dr. Khurana has received research support from Tiziana Life Sciences. Dr. Khurana has received intellectual property interests from a discovery or technology relating to health care.
No disclosure on file
Christopher Gomez, MD, PhD (University of Chicago) Dr. Gomez has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Gomez has received research support from Nih.
Susan L. Perlman, MD (UCLA) Dr. Perlman has nothing to disclose.